Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798827 | 1.00 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL14519354 | 0.89 | MAPK11 (0.81) | MAPK11MAPK14 | |
| SCHEMBL16316744 | 0.87 | MAPK11 (0.81) | MAPK11MAPK14 | |
| SCHEMBL14519350 | 0.87 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL14519351 | 0.87 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL6210833 | 0.87 | MAPK11 (0.77) | MAPK11MAPK14 | |
| SCHEMBL6210836 | 0.87 | MAPK11 (0.77) | MAPK11MAPK14 | |
| SCHEMBL5253769 | 0.86 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL14519349 | 0.86 | MAPK11 (0.79) | MAPK11MAPK14 | |
| SCHEMBL5256720 | 0.85 | MAPK11 (0.74) | MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10443039-B2 | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor | BIOVENTURES, LLC (US) | 2019-10-15 | — | — | US | claimed |
| EP-2205252-B1 | INHIBITION OF DENDRITIC CELL-DRIVEN REGULATORY T CELL ACTIVATION AND POTENTIATION OF TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES BY INTERLEUKIN-15 AND MAP KINASE INHIBITOR | UNIV ARKANSAS (US) | 2017-04-05 | — | — | EP | claimed |
| US-20140037579-A1 | Inhibition of Dendritic Cell-Driven Regulatory T Cell Activation and Potentiation of Tumor Antigen-Specific T Cell Responses by Interleukin-15 and MAP Kinase Inhibitor | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-02-06 | — | — | US | claimed |
| US-8546137-B2 | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2013-10-01 | — | — | US | claimed |
| EP-2205252-A2 | INHIBITION OF DENDRITIC CELL-DRIVEN REGULATORY T CELL ACTIVATION AND POTENTIATION OF TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES BY INTERLEUKIN-15 AND MAP KINASE INHIBITOR | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2010-07-14 | — | — | EP | claimed |
| US-20090136447-A1 | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor | BIOVENTURES, LLC | 2009-05-28 | — | — | US | claimed |
| WO-2009042215-A2 | INHIBITION OF DENDRITIC CELL-DRIVEN REGULATORY T CELL ACTIVATION AND POTENTIATION OF TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES BY INTERLEUKIN-15 AND MAP KINASE INHIBITOR | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2009-04-02 | — | — | WO | claimed |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | MAPK11 2502/4885MAPK14 3777/4885 |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | MAPK11 96/4885MAPK14 12/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | MAPK11 2502/4885MAPK14 3777/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | MAPK11 4504/4885MAPK14 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.